세계의 핵산 치료제 CDMO 시장 - 지역 분석 : 화학 합성법, 제품 유형, 질병 유형, 최종 사용자, 지역별 분석, 예측(2025-2035년)

Global Nucleic Acid Therapeutics CDMO Market Industry Overview

The global nucleic acid therapeutics CDMO market is experiencing rapid growth, driven by several key factors. The rising demand for nucleic acid-based therapies, such as mRNA, DNA, and RNA treatments, is a major contributor, particularly following the success of mRNA vaccines for COVID-19. Technological advancements in production processes, including innovations in lipid nanoparticle delivery systems and viral vector manufacturing, are enabling more efficient, scalable production. Additionally, the increase in partnerships and investments between biotechnology companies and CDMOs has fueled further growth, as biotech firms outsource production to meet the rising demand. Regulatory advancements and the fast-tracking of approvals for therapies have also created a favorable environment for nucleic acid therapeutics. Finally, the ongoing demand for gene therapies and the lessons learned from the pandemic have underscored the importance of nucleic acid-based treatments, ensuring the continued expansion of nucleic acid therapeutics CDMO market.

Several key factors are driving the growth of the nucleic acid therapeutics CDMO market. First, the increasing demand for nucleic acid-based therapies, particularly mRNA, DNA, and RNA treatments, is fueling market expansion. The success of mRNA vaccines during the COVID-19 pandemic has significantly accelerated interest in these therapies, creating a sustained need for production capacity.

Second, technological advancements in manufacturing, such as improvements in lipid nanoparticle delivery systems and viral vector production, have made large-scale production of these complex molecules more efficient and cost-effective. Additionally, the rise in strategic partnerships and investments between biotech firms and CDMOs has further boosted the sector, as companies seek to outsource production to specialized manufacturers. Regulatory advancements, including faster approval processes, have also contributed to the growth, ensuring quicker market access for new nucleic acid-based therapies. Finally, the growing application of gene therapies for a range of genetic disorders has increased the demand for specialized manufacturing services, further propelling the market forward.

Despite the significant opportunities, several challenges persist in the nucleic acid therapeutics CDMO market. One of the primary obstacles is the complexity of manufacturing nucleic acid-based therapies. The production of mRNA, DNA, and RNA therapies requires highly specialized and precise technologies, which can be difficult to scale up. Ensuring consistency, purity, and yield while maintaining regulatory compliance adds additional layers of complexity. Moreover, the production process is often resource-intensive, requiring advanced facilities, specialized equipment, and a skilled workforce, which can increase operational costs. Another challenge is the limited number of CDMOs with the necessary capabilities and infrastructure to handle the large-scale production of these therapies. This leads to supply chain bottlenecks and delays, particularly as the demand for nucleic acid therapeutics continues to grow. Additionally, regulatory hurdles, including the need for stringent quality control and compliance with international standards, can slow down the approval and commercialization process. These challenges underscore the need for continued innovation, investment, and collaboration to overcome barriers and fully capitalize on the opportunities in the nucleic acid therapeutics CDMO market.

Market Lifecycle Stage of Nucleic Acid Therapeutics CDMO

The global nucleic acid therapeutics CDMO market is currently in a phase of rapid expansion and maturation. As the demand for nucleic acid-based therapies, such as mRNA and gene therapies, continues to grow, CDMOs are scaling up production capabilities to meet the increasing needs of biotech and pharmaceutical companies. This phase is characterized by significant technological advancements, investment influx, and the establishment of strategic partnerships between CDMOs and biopharma companies. Many CDMOs are upgrading their facilities to include advanced capabilities in areas such as lipid nanoparticle formulation and viral vector production, which are critical for the success of nucleic acid-based therapeutics.

The market is also witnessing an accelerated shift toward commercial-scale manufacturing as clinical trials for nucleic acid therapies move toward commercialization. Regulatory processes have become more streamlined, especially in response to the COVID-19 pandemic, which has allowed for faster approval timelines and broader market adoption. However, as the market matures, challenges around scalability, cost-efficiency, and maintaining high-quality standards continue to persist, making it crucial for CDMOs to continually invest in innovation and operational optimization.

Impact for Nucleic Acid Therapeutics CDMO

The nucleic acid therapeutics CDMO market is at the forefront of a transformative shift in biopharmaceutical manufacturing, driven by the accelerating adoption of RNA-based and gene therapies. These therapies, including mRNA, DNA, and RNA-based treatments, are revolutionizing the way diseases, particularly genetic disorders, cancers, and viral infections, are treated. The ability to produce and scale these therapies efficiently is heavily reliant on the expertise of Contract Development and Manufacturing Organizations (CDMOs) that specialize in complex biopharmaceutical manufacturing processes.

Key technological advancements in the nucleic acid therapeutics CDMO market include:

• Lipid Nanoparticle (LNP) Technology: The use of LNPs has become crucial for the delivery of mRNA and RNA therapies. CDMOs with expertise in LNP formulation are well-positioned to support the growing demand for RNA-based vaccines and gene therapies. These innovations are enhancing the efficiency of nucleic acid delivery systems and improving therapeutic outcomes.
• Viral Vector Production: The manufacturing of viral vectors, which are essential for gene therapies, has seen significant advancements. CDMOs that specialize in viral vector production are increasingly in demand, as gene therapies using viral vectors are being developed for a wide range of diseases.
• Automated Manufacturing Systems: Automation and continuous bioprocessing are revolutionizing nucleic acid therapeutics production by enabling scalable, cost-effective, and efficient manufacturing. Automation minimizes human error and ensures consistency and purity in the production of complex molecules like mRNA.
• CRISPR and Gene Editing Technologies: CRISPR gene editing has expanded the scope of nucleic acid-based therapies. CDMOs are leveraging CRISPR technology to support the development and manufacturing of gene-editing therapies that can potentially cure genetic disorders at their root cause.

Regulatory Evolution and Approval Processes in Nucleic Acid Therapeutics CDMO Market:

The regulatory environment has been adapting to meet the needs of the fast-evolving nucleic acid therapeutics landscape. Authorities like the U.S. FDA and European Medicines Agency (EMA) have fast-tracked approval processes for RNA-based therapies, particularly in response to the global demand for COVID-19 vaccines.

Regulatory agencies are also increasingly providing clearer guidelines for the manufacturing and testing of gene therapies, which has encouraged more biotech firms to enter the nucleic acid therapeutics space. This shift has created a favorable environment for CDMOs, who play a key role in ensuring that therapies meet stringent regulatory standards for clinical trials and commercial production.

Impact of mRNA Vaccines:

The success of mRNA vaccines during the COVID-19 pandemic has had a profound impact on the nucleic acid therapeutics CDMO market. It has proven the efficacy and speed at which nucleic acid-based therapies can be developed and deployed, which has greatly accelerated the adoption of mRNA technologies for other diseases, including cancer and genetic disorders. This shift has led to an increased reliance on CDMOs to manufacture mRNA vaccines and other nucleic acid therapies at an unprecedented scale.

As vaccine development pipelines expand, particularly in oncology and infectious diseases, the demand for CDMOs with mRNA capabilities is expected to grow. CDMOs are increasingly investing in the necessary facilities, equipment, and expertise to handle the complexity and scale of mRNA production.

Gene Therapy Expansion:

Gene therapies, particularly those using viral vectors and RNA technologies, are becoming more prevalent for treating genetic diseases. Gene therapies offer potential cures for conditions previously thought to be untreatable, such as sickle cell anemia, muscular dystrophy, and hemophilia.

The increased development of these therapies is boosting the demand for CDMOs with the expertise and infrastructure to support the complex and often personalized manufacturing processes associated with gene therapies. This includes the production of plasmids, viral vectors, and other gene-editing technologies such as CRISPR. As gene therapies move closer to commercialization, CDMOs with specialized manufacturing capabilities are poised to play a critical role in bringing these therapies to market at scale.

Global Demand and Scalability:

With the rising global demand for nucleic acid therapeutics, there is a growing need for CDMOs to offer large-scale manufacturing capabilities. The scalability of production is critical, as these therapies often need to be produced in large volumes to meet worldwide demand, particularly for vaccines and gene therapies.

CDMOs are expanding their facilities and increasing production capacity to meet this demand. The ability to scale efficiently, while maintaining high-quality standards and regulatory compliance, is a key competitive advantage. The demand for commercial-grade mRNA vaccines and other therapies is projected to remain strong, creating a long-term opportunity for CDMOs to capitalize on this growth.

Market Segmentation for Nucleic Acid Therapeutics CDMO Market:

Segmentation 1: by Product Type

• Standard Nucleic Acid
• Micro-Scale Nucleic Acid
• Custom Nucleic Acid
• Modified Nucleic Acid
• Primers
• Probes
• Other Nucleic Acid
• Other Services

The global nucleic acid therapeutics CDMO market (by product type) is expected to be dominated by the standard nucleic acid segment.

Segmentation 2: by Disease Type

• Genetic Disease
• Infectious Disease

The global nucleic acid therapeutics CDMO market (by disease type) is expected to be dominated by genetic disease.

Segmentation 3: By Chemical Synthesis Method

• Solid-Phase Oligonucleotide Synthesis
• Liquid-Phase Oligonucleotide Synthesis

The global nucleic acid therapeutics CDMO market (by chemical synthesis method) is expected to be dominated by solid-phase oligonucleotide synthesis.

Segmentation 4: By End User

• Pharmaceutical Companies
• Academic Research Institute
• Diagnostic Laboratories

The global nucleic acid therapeutics CDMO market (by end-user) is expected to be dominated by pharmaceutical companies.

Segmentation 5: by Region

• North America: U.S., and Canada
• Europe: Germany, U.K., France, Italy, Spain, and Rest-of-Europe
• Asia-Pacific: China, Japan, South Korea, India, Australia, and Rest-of-Asia-Pacific
• Rest-of-the-World

The global nucleic acid therapeutics CDMO market (by region) is dominated by the North America region.

Recent Developments in the Global Nucleic Acid Therapeutics CDMO Market

• In January 2023, Agilent Technologies, Inc. invested $725 million to increase its manufacturing capacity for therapeutic nucleic acids.
• In March 2022, IMM, a partner of VGXI, has recently announced that it received a $12 million grant from the National Institutes of Health (NIH) to support the Phase 1 clinical trial of a DNA vaccine aimed at preventing Alzheimer's disease. The vaccine will be manufactured using VGXI's expertise in contract manufacturing of DNA plasmids for human clinical trials, produced in accordance with GMP standards.
• In April 2022, BACHEM partnered with Eli Lilly and Company to develop and manufacture active pharmaceutical ingredients based on oligonucleotides, a rising new class of complex molecules.
• In September 2021, AGC Biologics expanded the company's Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.
• In August 2022, Codexis and Molecular Assemblies announced the execution of a commercial license and enzyme supply agreement for an optimized TdT enzyme for enzymatic DNA synthesis.
• In June 2020, OliX Pharmaceuticals, Inc. partnered with LGC Biosearch Technologies Inc. to scale up the production of OliX's OLX301D therapeutic candidate.

Demand - Drivers and Limitations for Nucleic Acid Therapeutics CDMO

Market Demand Drivers for Nucleic Acid Therapeutics CDMO:

• Growing demand for nucleic acid therapeutics applications to treat chronic and genetic diseases.
• Increasing FDA or European Medicines Agency (EMA) approvals of nucleic acid Therapeutics
• Advancements in manufacturing units for producing nucleic acid by CDMO.

Market Restraints for Nucleic Acid Therapeutics CDMO:

• Substantial variation in nucleic acid leads to complications in therapeutic classification.
• Lack of expertise in developing nucleic acid therapeutics

Market Opportunities for Nucleic Acid Therapeutics CDMO:

• Continued research and development activities for manufacturing innovative nucleic acid therapeutics forcing pharmaceutical companies to expand their businesses.
• Pharmaceutical Firms Becoming More Outsourcing-Oriented

How can nucleic acid therapeutics CDMO market report add value to an organization?

Workflow/Innovation Strategy: The nucleic acid therapeutics CDMO market (by product type) has been segmented into standard nucleic acid, micro-scale nucleic acid, custom nucleic acid, modified nucleic acid, primers, probes, other nucleic acid, and other services. Moreover, the study provides the reader with a detailed understanding of the different applications of nucleic acid therapeutics CDMO in raw material preparation, upstream processing, downstream processing, and packaging.

Growth/Marketing Strategy: Cell and gene therapy biomanufacturing is being used for raw material preparation, upstream processing, downstream processing, and packaging. Various companies are providing products and services to aid in the manufacturing of various cell and gene therapies, which is also the key strategy for market players to excel in the current nucleic acid therapeutics CDMO market.

Competitive Strategy: Key players in the global nucleic acid therapeutics CDMO market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global nucleic acid therapeutics CDMO market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the nucleic acid therapeutics CDMO market.

Methodology

Key Considerations and Assumptions in Nucleic Acid Therapeutics CDMO Market Engineering and Validation

• The base year considered for the calculation of the nucleic acid therapeutics CDMO market size is 2024. The historical year analysis has been done from FY2021 to FY2023, and the market size has been estimated for FY2024 and projected for the period 2025-2035.
• The regional distribution of the market revenue has been estimated to be the same as the company's net revenue distribution. All the numbers have been adjusted off to two digits after decimal for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. The CAGR has been calculated for the forecast period 2025-2035.
• Nucleic acid therapeutics CDMO market has been mapped based on different types of products available in the market for various applications. All key companies having a significant number of offerings for the global nucleic acid therapeutics CDMO market have been considered and profiled in the report.
• The primary respondent's verification has been considered to finalize the estimated market for the global nucleic acid therapeutics CDMO market.
• The latest annual reports of each market player have been taken into consideration for nucleic acid therapeutics CDMO market revenue calculation.
• Market strategies and developments of key players have been considered for the calculation of the sub-segment split.
• The base currency considered for the nucleic acid therapeutics CDMO market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website.

Primary Research

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding of the numbers of the various markets for market type
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Central Drugs Standard Control Organization (CDSCO), Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS), European Medicines Agency (EMA), Institute for Health Metrics and Evaluation (IHME), Medicines and Healthcare Products Regulatory Agency (MHRA), National Organization for Rare Disorders (NORD), Pharmaceuticals and Medical Devices Agency (PMDA), World Health Organization (WHO), and World Intellectual Property Organization (WIPO)
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their portfolio
• Gold standard magazines, journals, whitepapers, press releases, and news articles
• Databases

The key data points taken from the secondary sources include:

• Segmentations, split-ups, and percentage shares
• Data for market value
• Key industry trends of the top players in the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis for Nucleic Acid Therapeutics CDMO

The nucleic acid therapeutics CDMO (Contract Development and Manufacturing Organization) market is highly competitive, with several prominent players that specialize in the development and manufacturing of nucleic acid-based therapies, including mRNA, DNA, RNA, and gene therapies. These companies offer specialized services ranging from process development to large-scale commercial manufacturing. The competitive landscape is shaped by factors such as technological innovation, production capacity, regulatory compliance, and strategic partnerships with biotech firms and pharmaceutical companies.

Some of the prominent companies in nucleic acid therapeutics CDMO market are:

• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Agilent Technologies, Inc
• ST Pharm
• GeneOne Life Science
• LGC Science Group Holdings Limited
• BACHEM
• Eurofins Scientific
• Kaneka Corporation
• CMIC HOLDINGS Co., Ltd
• Nippon Shkubai Co., Ltd
• AGC Biologics
• Codexis, Inc.
• Asymchem Inc.
• Maravai LifeSciences Holdings, Inc.

Table of Contents

Executive Summary

Scope of Study

Research Methodology

1. Global Nucleic Acid Therapeutics CDMO Market Overview

• 1.1 Industry Outlook
  • 1.1.1 Introduction
  • 1.1.2 Market Overview and Ecosystem
  • 1.1.3 Key Trends
  • 1.1.4 Opportunity Assessment
  • 1.1.5 Patent Analysis
  • 1.1.6 Production Capability
  • 1.1.7 Preferred Techniques by CDMO
    • 1.1.7.1 Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
    • 1.1.7.2 Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
    • 1.1.7.3 Preferred Techniques by CDMOs for Nucleic Acid Purification
  • 1.1.8 Factors Considered While Outsourcing to CDMO
  • 1.1.9 Regulatory Framework
  • 1.1.10 Current Nucleic Acid Therapeutics CDMO Landscape
  • 1.1.11 Significant Usage of Nucleic Acid Therapeutics
  • 1.1.12 Types of Nucleic Acid Synthesized for Therapeutics
    • 1.1.12.1 Anti-sense Oligonucleotides and DNA Aptamers
    • 1.1.12.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
    • 1.1.12.3 MicrRNAs (miRNAs)
    • 1.1.12.4 Ribozymes
    • 1.1.12.5 Circular RNA
• 1.2 Market Dynamics
  • 1.2.1 Market Opportunities and Trends
  • 1.2.2 Market Drivers
    • 1.2.2.1 Impact Analysis
  • 1.2.3 Market Restraints
    • 1.2.3.1 Impact Analysis

2. Global Nucleic Acid Therapeutics CDMO Market Analysis (by Chemical Synthesis Method), $Million, 2023-2035

• 2.1 Opportunity Assessment
• 2.2 Growth-Share Matrix
• 2.3 Solid-Phase Oligonucleotide Synthesis (SPOS)
  • 2.3.1 Column-based Method
  • 2.3.2 Microarray-based Method
• 2.4 Liquid-Phase Oligonucleotide Synthesis (LPOS)

3. Global Nucleic Acid Therapeutics CDMO Market Analysis (By Product), $Million, 2023-2035

• 3.1 Opportunity Assessment
• 3.2 Growth-Share Matrix
  • 3.2.1 Standard Nucleic Acid
  • 3.2.2 Micro-Scale Nucleic Acid
  • 3.2.3 Custom Nucleic Acid
  • 3.2.4 Modified Nucleic Acid
  • 3.2.5 Primers
  • 3.2.6 Probes
  • 3.2.7 Other Nucleic Acid
  • 3.2.8 Other Services

4. Global Nucleic Acid Therapeutics CDMO Market Analysis (By Disease Type), $Million, 2023-2035

• 4.1 Opportunity Assessment
• 4.2 Growth-Share Matrix
• 4.3 Genetic Disease
• 4.4 Infectious Disease

5. Global Nucleic Acid Therapeutics CDMO Market Analysis (By End User), $Million, 2023-2035

• 5.1 Opportunity Assessment
• 5.2 Growth-Share Matrix
• 5.3 Pharmaceutical Companies
• 5.4 Academic Institution
• 5.5 Diagnostic Laboratories

6. Global Nucleic Acid Therapeutics CDMO Market Analysis (By Region), $Million, 2023-2035

• 6.1 North America
  • 6.1.1 Key Findings
  • 6.1.2 Market Dynamics
  • 6.1.3 Market Sizing and Forecast
    • 6.1.3.1 By Chemical Synthesis Method
    • 6.1.3.2 By Country
      • 6.1.3.2.1 U.S.
        • 6.1.3.2.1.1 By Chemical Synthesis Method
      • 6.1.3.2.2 Canada
        • 6.1.3.2.2.1 By Chemical Synthesis Method
• 6.2 Europe
  • 6.2.1 Key Findings
  • 6.2.2 Market Dynamics
  • 6.2.3 Market Sizing and Forecast
    • 6.2.3.1 By Chemical Synthesis Methods
    • 6.2.3.2 By Country
      • 6.2.3.2.1 Germany
        • 6.2.3.2.1.1 By Chemical Synthesis Method
      • 6.2.3.2.2 U.K.
        • 6.2.3.2.2.1 By Chemical Synthesis Method
      • 6.2.3.2.3 France
        • 6.2.3.2.3.1 By Chemical Synthesis Method
      • 6.2.3.2.4 Italy
        • 6.2.3.2.4.1 By Chemical Synthesis Method
      • 6.2.3.2.5 Spain
        • 6.2.3.2.5.1 By Chemical Synthesis Method
      • 6.2.3.2.6 Rest of Europe
        • 6.2.3.2.6.1 By Chemical Synthesis Method
• 6.3 Asia-Pacific
  • 6.3.1 Key Findings
  • 6.3.2 Market Dynamics
  • 6.3.3 Market Sizing and Forecast
    • 6.3.3.1 By Chemical Synthesis Method
    • 6.3.3.2 By Country
      • 6.3.3.2.1 Japan
        • 6.3.3.2.1.1 By Chemical Synthesis Method
      • 6.3.3.2.2 China
        • 6.3.3.2.2.1 By Chemical Synthesis Method
      • 6.3.3.2.3 India
        • 6.3.3.2.3.1 By Chemical Synthesis Method
      • 6.3.3.2.4 South Korea
        • 6.3.3.2.4.1 By Chemical Synthesis Method
      • 6.3.3.2.5 Australia
        • 6.3.3.2.5.1 By Chemical Synthesis Method
      • 6.3.3.2.6 Rest-of-Asia-Pacific
        • 6.3.3.2.6.1 By Chemical Synthesis Method
• 6.4 Rest-of-the-World
  • 6.4.1 Key Findings
  • 6.4.2 Market Dynamics
  • 6.4.3 Market Sizing and Forecast
    • 6.4.3.1 By Chemical Synthesis Method

7. Global Nucleic Acid Therapeutics CDMO Market -Competitive Benchmarking and Company Profiles

• 7.1 Competitive Landscape
• 7.2 Competitive Landscape
  • 7.2.1 Key Strategies and Developments by Company
    • 7.2.1.1 Funding Activities
    • 7.2.1.2 Mergers and Acquisitions
    • 7.2.1.3 Regulatory Approvals
    • 7.2.1.4 Partnerships, Collaborations and Business Expansions
  • 7.2.2 Market Share Analysis, 2024
• 7.3 Company Profiles
  • 7.3.1 Agilent Technologies
    • 7.3.1.1 Company Overview
    • 7.3.1.2 Product Portfolio
    • 7.3.1.3 Target Customers/End Users
    • 7.3.1.4 Analyst View
  • 7.3.2 AGC Biologics
    • 7.3.2.1 Company Overview
    • 7.3.2.2 Product Portfolio
    • 7.3.2.3 Target Customers/End Users
    • 7.3.2.4 Analyst View
  • 7.3.3 Asymchem, Inc.
    • 7.3.3.1 Company Overview
    • 7.3.3.2 Product Portfolio
    • 7.3.3.3 Target Customers/End Users
    • 7.3.3.4 Analyst View
  • 7.3.4 BACHEM
    • 7.3.4.1 Company Overview
    • 7.3.4.2 Product Portfolio
    • 7.3.4.3 Target Customers/End Users
    • 7.3.4.4 Analyst View
  • 7.3.5 Catalent, Inc.
    • 7.3.5.1 Company Overview
    • 7.3.5.2 Product Portfolio
    • 7.3.5.3 Target Customers/End Users
    • 7.3.5.4 Analyst View
  • 7.3.6 CMIC Holdings CO. Ltd.
    • 7.3.6.1 Company Overview
    • 7.3.6.2 Product Portfolio
    • 7.3.6.3 Target Customers/End Users
    • 7.3.6.4 Analyst View
  • 7.3.7 Codexis, Inc.
    • 7.3.7.1 Company Overview
    • 7.3.7.2 Product Portfolio
    • 7.3.7.3 Target Customers/End Users
    • 7.3.7.4 Analyst View
  • 7.3.8 Danaher Corporation
    • 7.3.8.1 Company Overview
    • 7.3.8.2 Product Portfolio
    • 7.3.8.3 Target Customers/End Users
    • 7.3.8.4 Analyst View
  • 7.3.9 Eurofins Scientific
    • 7.3.9.1 Company Overview
    • 7.3.9.2 Product Portfolio
    • 7.3.9.3 Target Customers/End Users
    • 7.3.9.4 Analyst View
  • 7.3.10 GeneOne Life Sciences
    • 7.3.10.1 Company Overview
    • 7.3.10.2 Product Portfolio
    • 7.3.10.3 Target Customers/End Users
    • 7.3.10.4 Analyst View
  • 7.3.11 LGC Science Group Holdings Limited
    • 7.3.11.1 Company Overview
    • 7.3.11.2 Product Portfolio
    • 7.3.11.3 Target Customers/End Users
    • 7.3.11.4 Analyst View
  • 7.3.12 Maravai Life Sciences Holdings, Inc.
    • 7.3.12.1 Company Overview
    • 7.3.12.2 Product Portfolio
    • 7.3.12.3 Target Customers/End Users
    • 7.3.12.4 Analyst View
  • 7.3.13 Merck KGaA
    • 7.3.13.1 Company Overview
    • 7.3.13.2 Product Portfolio
    • 7.3.13.3 Target Customers/End Users
    • 7.3.13.4 Analyst View
  • 7.3.14 ST Pharm
    • 7.3.14.1 Company Overview
    • 7.3.14.2 Product Portfolio
    • 7.3.14.3 Target Customers/End Users
    • 7.3.14.4 Analyst View
  • 7.3.15 Thermo Fisher Scientific, Inc.
    • 7.3.15.1 Company Overview
    • 7.3.15.2 Product Portfolio
    • 7.3.15.3 Target Customers/End Users
    • 7.3.15.4 Analyst View

8. Research Methodology